Physician profile
Philip Chu
NPI 1235543356
$2,921.32
in general payments reported to CMS, 2019-2025
13 companies · $761 in 2025
The $761 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.25 · 2020: $162 · 2021: $106 · 2022: $157 · 2023: $525 · 2024: $1,144 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873 · Consulting Fee: $400 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.48 |
| Consulting Fee | $400.00 |
| Education | $156.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $746.94 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Janssen Biotech, INC. | $529.11 | 2024-2025 | Tremfya |
| Abbvie INC. | $494.88 | 2021-2024 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $228.60 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $221.85 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $165.95 | 2019-2020 | |
| Novo Nordisk INC | $154.64 | 2020-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $133.43 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $100.75 | 2025 | Repatha, Krystexxa |
| Alexion Pharmaceuticals, INC. | $100.28 | 2024 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $17.41 | 2021 | |
| Shire North American Group INC | $14.89 | 2019 | |
| Janssen Scientific Affairs, LLC | $12.59 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.